Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

COVID-19

Chronic Hand Eczema

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Case-Based Roundtable

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Perspectives in Dermatology

Polls

Editorial Advisory Board

Partners

Subscribe

Kaitlyn Bader is the assistant managing editor of 

 and joined the MJH Life Sciences team in June 2022. She attended Otterbein University in Westerville, Ohio, and earned a Bachelor of Arts degree in literary studies with minors in creative writing and film studies. Prior to health care news, Kaitlyn worked in industrial marketing. She enjoys cooking, reading, and tending to her house plants.

Articles

Treatment with delgocitinib led to a significant decrease in the expression of inflammatory markers that were elevated in severe cases compared with mild cases at baseline.

Delgocitinib Reduces Inflammation and Restores Skin Barrier in CHE as a Topical Pan-JAK Inhibitor

Marie Bosslett is the assistant editor of 

 and joined the MJH Life Sciences team in October 2024. She attended Loyola University Maryland in Baltimore and earned a Bachelor of Arts in Communication with minors in marketing and writing. When she’s not writing, Marie enjoys going to concerts, reading on the beach, and spending time with friends and family.

Regenerative methods such as cell therapy and platelet-rich plasma showed promising results in patient repigmentation.

Regenerative Medicine Proves to Be Effective for Vitiligo Treatment

Logan Lutton is a contributing author for 

If granted, guselkumab will be approved to treat children ages 6 and younger with severe plaque psoriasis and children ages 5 and younger with juvenile psoriatic arthritis.

Johnson & Johnson Submits 2 sBLAs for Guselkumab for Pediatric Psoriasis and Juvenile PsA

Read more about acne treatment tips shared at the 2024 SDPA Fall Conference by experts such as Shanna Miranti, MPAS, PA-C, and Hilary Baldwin, MD.

Acne Treatment Insights From SDPA Fall

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

Case Based Peer Perspectives

Real-world, case-based insights, with experts sharing how they would approach and treat a specific scenario, including what they are looking for in a diagnosis. Hear about complex cases you could encounter, often accompanied by real patient images.

1rem

various aspects of vitiligo management through case-based discussions and insights including navigating emotional and clinical challenges to balancing treatment options with coverage constraints.

Beyond the Stigma: Patient Stories in Vitiligo Management

Videos

Ted Lain, MD, MBA, FAAD offers insights into navigating the emotional and clinical challenges in vitiligo management. 

Insights into Navigating the Emotional and Clinical Challenges in Vitiligo Management

Ted Lain, MD, MBA, FAAD discusses balancing vitiligo treatments with coverage challenges.

Balancing Vitiligo Treatments with Coverage Challenges

Ted Lain, MD, MBA, FAAD discusses a case which addresses location-specific concerns and treatment challenges in vitiligo management. 

Case-Based Insights: Addressing Location-Specific Concerns and Treatment Challenges in Vitiligo Management

Ted Lain, MD, MBA, FAAD discusses navigating the treatment paradigm for vitiligo. 

Navigating the Treatment Paradigm for Vitiligo: Efficacy, MOA, and Long-Term Use of FDA-Approved Topical Ruxolitinib